Table 3 Clinical and laboratory co-variates and therapy of subjects with haematological cancer and COVID-19.

Age, median (IQR), years

35 (26, 37)

39 (22, 54)

 Male sex

2

5

  Laboratory confirmed

5

8

  Clinically diagnosed

0

0

  Mild

0

0

  Common

3

1

  Severe

1

3

  Critical

1

4

  Patchy shadows

1

1

  Ground-glass opacity

2

6

  Air space consolidation/whiteout

1

0

  NA^a

1

1

  WBC, median (IQR), ×10E + 9/L (3.5–9.5)

3.9 (2.6, 7.8)

2.6 (0.5, 11.6)

  Neutrophils, median (IQR), ×10E + 9/L (1.8–6.3)

2.7 (1.1, 6.8)

0.7 (0.2, 6.5)

  Lymphocytes, median (IQR), ×10E + 9/L (1.1–3.2)

0.7 (0.5, 0.9)

0.5 (0.2, 0.7)

  Platelets, mean (SD), ×10E + 9/L (125–350)

107.2 ± 86.0

54.1 ± 45.1

  Haemoglobin, mean (SD), g/L (male, 130–175; female, 115–150)

81.0 ± 19.3

71.9 ± 20.6

  Prothrombin time, median (IQR), s (11.0–16.0)

16.2 (15.6, 16.5)

16.4 (13.7, 16.9)

  Activated partial thromboplastin time, mean (SD), s (28.0–43.5)

44.7 ± 10.9

37.5 ± 16.3

  D-dimer, median (IQR), mg/L (<0.5)

0.6 (0.6, 0.6)

1.3 (0.8, 2.4)

  Alanine aminotransferase, mean (SD), U/L (9–52)

18.7 ± 10.3

18.9 ± 10.6

  Aspartate aminotransferase, mean (SD), U/L (14–36)

26 ± 10

24 ± 14

  Total bilirubin, median (IQR), μmol/L (3–22)

11.1 (9.6, 12.9)

11.7 (6.0, 17.2)

  Blood urea nitrogen, mean (SD), mmol/L (2.5–6.1)

4.7 ± 2.2

5.5 ± 3.2

  Serum creatinine, median (IQR), μmol/L (46–92)

44 (41, 70)

56 (43, 68)

  Lactate dehydrogenase, median (IQR), U/L, (114–240)

275 (261, 296)

184.0 (155, 413)

  Procalcitonin, mean (SD), ng/mL (<0.5)

1.2 ± 1.2

4.0 ± 4.2

  C-reactive protein, median (IQR), mg/L (<8.00)

121 (37, 144)

68 (64, 115)

  Other viruses

3

4

  Bacteria

3

8

  Fungi

3

6

 Complications

  ARDS

0

6

  Acute renal failure

0

1

  Sepsis

1

1

  Umifenovir

3

5

  Interferon

2

4

  Antibiotics

3

6

  Corticosteroids

1

3

  Oxygen inhalation

3

7

  Non-invasive ventilation

0

2

  Mechanical ventilation

0

1